Atara Biotherapeutics, Inc. (ATRA)
$
4.59
-0.12 (-2.61%)
Key metrics
Financial statements
Free cash flow per share
-4.0609
Market cap
37.5 Million
Price to sales ratio
0.3108
Debt to equity
-1.3713
Current ratio
0.8184
Income quality
-1.5584
Average inventory
0
ROE
-0.7912
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atara Biotherapeutics, Inc. is an innovative company focused on off-the-shelf T-cell immunotherapy, dedicated to developing treatments for patients suffering from cancer, autoimmune disorders, and viral diseases in the United States. Currently, it is advancing tabelecleucel, a T-cell immunotherapy undergoing Phase 3 clinical trials to treat Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors like nasopharyngeal carcinoma. Additionally, Atara is working on next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 targeting mesothelin, along with ATA2431 and ATA3219 focused on B-cell malignancies, in addition to ATA188 for multiple sclerosis. The company is also developing the ATA368 program for patients with cancers associated with human papillomavirus. Atara Biotherapeutics has established a license agreement with Memorial Sloan Kettering Cancer Center, alongside a research and development collaboration with QIMR Berghofer Medical Research Institute, as well as strategic partnerships with H. Lee Moffitt Cancer Center and Bayer AG for the development of mesothelin-targeted CAR T-cell therapies designed for solid tumors. Incorporation in 2012 marked the beginning of the company, which is now headquartered in South San Francisco, California. The gross profit stands at $99,560,000.00 highlighting the company's profitability from core operations. The company's stock is identified with the symbol '$ATRA' in the market. The income before tax ratio is $0.27 reflecting the pre-tax margin. The company reported an income before tax of $32,719,000.00 showcasing its pre-tax profitability. The financial data pertains to the fiscal year $2025. Atara Biotherapeutics, Inc. is classified as a small-cap player with a market capitalization of $37,537,525.00. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation within the Healthcare sector. The stock is affordable at $12.05 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 462,054.00 indicating lower market activity. This dynamic presence in the market reflects the company's commitment to advancing therapeutic solutions and enhancing patient care.
Is Atara Biotherapeutics, Inc. (ATRA) a good investment?
Investing in Atara Biotherapeutics, Inc. (ATRA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Atara Biotherapeutics, Inc. (ATRA)'s stock forecast?
Analysts predict Atara Biotherapeutics, Inc. stock to fluctuate between $3.92 (low) and $19.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Atara Biotherapeutics, Inc.'s market capitalization?
As of 2026-03-27, Atara Biotherapeutics, Inc.'s market cap is $37,537,525, based on 8,178,110 outstanding shares.
How does Atara Biotherapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Atara Biotherapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Atara Biotherapeutics, Inc. (ATRA) stock?
To buy Atara Biotherapeutics, Inc. (ATRA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATRA. Place an order (Market, Limit, etc.).
What is the best time to invest in Atara Biotherapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Atara Biotherapeutics, Inc. stock ever split?
Atara Biotherapeutics, Inc.'s last stock split was 1:25 on 2024-06-20.
How did Atara Biotherapeutics, Inc. perform in the last earnings report?
Revenue: $120,772,000 | EPS: $2.61 | Growth: -122.87%.
Where can I find Atara Biotherapeutics, Inc.'s investor relations reports?
Visit https://www.atarabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Atara Biotherapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Atara Biotherapeutics, Inc. stock?
All-time high: $501 (2021-11-04) | All-time low: $3.92 (2026-02-23).
What are the key trends affecting Atara Biotherapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
globenewswire.com
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA).
newsfilecorp.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Atara between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
globenewswire.com
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”).
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATARA BIOTHERAPEUTICS, INC. (ATRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Wh.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $ATRA--Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRA.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $ATRA--ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATARA BIOTHERAPEUTICS, INC. (ATRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On January 16, 2025, Atara disclosed that it had re.
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
See all news
